Clinical trial NCT03075553: Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Official title: Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Blastic Plasmacytoid Dendritic Cell Neoplasm
Hepatosplenic T-Cell Lymphoma
HTLV-1 Infection
NK-Cell Lymphoma, Unclassifiable
Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative
Recurrent Adult T-Cell Leukemia/Lymphoma
Recurrent Anaplastic Large Cell Lymphoma
Recurrent Angioimmunoblastic T-cell Lymphoma
Recurrent Enteropathy-Associated T-Cell Lymphoma
Recurrent Mycosis Fungoides
Refractory Adult T-Cell Leukemia/Lymphoma
Refractory Anaplastic Large Cell Lymphoma
Refractory Angioimmunoblastic T-cell Lymphoma
Refractory Enteropathy-Associated T-Cell Lymphoma
Refractory Mycosis Fungoides
Refractory Nasal Type Extranodal NK/T-Cell Lymphoma
Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: National Cancer Institute (NCI)
First posted: 2017-03-09
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells.

Detailed description: PRIMARY OBJECTIVES:

I. To assess the clinical benefit of nivolumab in T-cell lymphomas, as measured by objective response rate (ORR) within 12 cycles according to the Lugano Classification Response Criteria (2014).

SECONDARY OBJECTIVES:

I. To assess safety and tolerability of the regimen in this patient population. II. To assess progression-free survival (PFS). III. To assess duration of response (DOR). IV. To assess overall survival (OS).

TERTIARY OBJECTIVES:

I. To evaluate T-cell/cytokine profile in the peripheral blood - peripheral blood specimens will be used to assess T-cell activation and cytokine up regulation as measures of treatment effect.

II. To evaluate intratumoral biomarkers- intratumoral cell populations and distribution, genetic variability, mutational burden and T-cell activation will be evaluated to identify potential biomarkers that correlate with response to therapy.

III. To assess the potential association between PD-L1/PD-1/PD-L2 expression on tumor and T-cells and/or PD-L1 soluble levels in plasma with clinical efficacy of PD-1 blockade.

OUTLINE:

Patients receive nivolumab intravenously (IV) over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive nivolumab IV over 60 minutes on day 1 of course 9. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 35 days, 100-120 days, 230-250 days, and 330-390 days.

Eligibility criteria: Inclusion Criteria:

* Relapsed or refractory T-cell lymphoma (TCL) biopsy-proven =\< 6 months prior to registration, including the following subtypes:

  * Peripheral T-cell lymphoma, not otherwise specified
  * Anaplastic large cell lymphoma, anaplastic lymphoma kinase (ALK) negative, primary systemic type
  * Angioimmunoblastic T-cell lymphoma
  * Extranodal natural killer (NK)/T-cell lymphoma, nasal type
  * Adult T-cell lymphoma/leukemia (human T-lymphotropic virus 1 \[HTLV1\]+)
  * Blastic NK-cell lymphoma
  * Enteropathy-associated T-cell lymphoma
  * Hepatosplenic gamma delta T-cell lymphoma
  * Transformed mycosis fungoides
  * T/NK-cell lymphoma, unclassifiable
* Measurable disease: subjects must have at least one lesion that is \> 15mm (1.5 cm) in the longest diameter on cross-sectional imaging and measureable in two perpendicular dimensions per computed tomography (spiral CT) or magnetic resonance imaging (MRI)
* After failure of allogeneic stem cell transplant (ASCT) or after failure of frontline therapy in subjects who declined or are not ASCT candidates
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
* White blood cell (WBC) \>= 3000/mm\^3
* Absolute neutrophil count (ANC) \>= 1500/mm\^3
* Platelet count \>= 100,000/mm\^3
* Hemoglobin \> 9.0 g/dL
* Total bilirubin =\< 1.5 x upper limit of normal (ULN) unless elevation due to Gilbert's Syndrome
* Aspartate transaminase (AST) =\< 2.5 x ULN
* Creatinine =\< 2.0 mg/dL
* Calculated creatinine clearance must be \>= 45 ml/min using the Cockcroft-Gault formula
* Negative serum or urine pregnancy test done =\< 7 days prior to registration, for persons of childbearing potential only Note: Persons of child-bearing potential (POCBP) must use appropriate method(s) of contraception; POCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug; men who are sexually active with POCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with POCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; persons who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception; should a person become pregnant or suspect being pregnant while participating in this study, the person should inform the treating physician immediately
* Provide written informed consent
* Willing to return to enrolling institution for follow-up during the Active Monitoring phase of the study
* Willing to provide tissue and blood samples for correlative research purposes

Exclusion Criteria:

* All primary cutaneous T-cell lymphomas
* Any of the following:

  * Pregnant women
  * Nursing women
  * Men or women of childbearing potential who are unwilling to employ adequate contraception
* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* Active, known or suspected autoimmune disease Note: subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment
* Use of systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications \< 14 days of registration Note: inhaled or topical steroids are permitted; \> 10 mg daily prednisone equivalents are permitted only in adrenal insufficiency in the absence of active autoimmune disease
* Prohibited treatments and or therapies

  * Autologous stem cell transplant (ASCT) =\< 12 weeks prior to first dose of the study drug
  * Prior treatments (window prior to registration):

    * Chemotherapy =\< 2 weeks
    * Nitrosureas =\< 6 weeks
    * Therapeutic anticancer antibodies =\< 4 weeks
    * Radio- or toxin immunoconjugates =\< 10 weeks
    * Radiation therapy =\< 3 weeks
    * Or major surgery =\< 2 weeks
  * Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways

    * Prior allogeneic stem cell transplant (SCT)
    * Chest radiation =\< 24 weeks prior to registration
* Immunocompromised patients, patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) and currently receiving antiretroviral therapy, active hepatitis B virus surface antigen (HBV sAg+), active hepatitis C (if Ab+ then PCR+) indicating acute or chronic infection
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
* Other active malignancy =\< 3 years prior to registration EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix NOTE: if there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer
* Active central nervous system (CNS) involvement or leptomeningeal involvement
* History of pancreatitis

Primary outcomes:
measure: Response Rate for Participants Who Achieve a CR or PR [CT-based Response]
timeFrame: Up to 390 days
Secondary outcomes:
measure: Response Rate for Participants Who Achieve a CMR or PMR [PET-CT-based Response]
timeFrame: Up to 390 days
measure: Duration of Response (DOR)
timeFrame: Up to 390 days
measure: Progression-Free Survival (PFS)
timeFrame: The time from registration to relapse or death due to any cause, an average of 2 years
measure: Overall Survival (OS)
timeFrame: The time from registration to death due to any cause, assessed up to 2 years
measure: Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Events
timeFrame: Up to 390 days
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Stephen Ansell
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bennani NN, Kim HJ, Pederson LD, Atherton PJ, Micallef IN, Thanarajasingam G, Nowakowski GS, Witzig T, Feldman AL, Ansell SM. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer. 2022 Jun;10(6):e004984. doi: 10.1136/jitc-2022-004984.